Children's Oncology Group's 2013 blueprint for research: Survivorship and outcomes

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages 1063-1068

  Armenian, Saro H ^a,b   Landier, Wendy ^a,b   Hudson, Melissa M ^a,b   Robison, Leslie L ^a,b   Bhatia, Smita ^a,b  

^a City of Hope ^*  (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Children's oncology group; Health related disparities; Late effects; Long term follow up guidelines; Survivorship and outcomes

Indexed keywords

ANTHRACYCLINE; RAZOXANE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVOR; CARDIOMYOPATHY; CHILD; CHILDHOOD CANCER; ETHNIC DIFFERENCE; FOLLOW UP; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; LYMPHOMA; METASTASIS; NEUROPSYCHOLOGY; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVARIAN RESERVE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; REPRODUCTIVE HEALTH; REVIEW;

CHILD; DELIVERY OF HEALTH CARE; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH; SURVIVAL RATE; SURVIVORS;

EID: 84876435918     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24422     Document Type: Review

References (55)

1. Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 2009; 18: 1033-1040.
2. Hudson MM, Neglia JP, Woods WG, et al. Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer 2012; 58: 334-343.
3. Bhatia S, Robison LL. Cancer survivorship research: Opportunities and future needs for expanding the research base. Cancer Epidemiol Biomarkers Prev 2008; 17: 1551-1557.
4. Bhatia S. Disparities in cancer outcomes: Lessons learned from children with cancer. Pediatr Blood Cancer 2011; 56: 994-1002.
5. Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer 2008; 113: 2575-2596.
6. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22: 4979-4990.
7. Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the childhood cancer survivor study cohort: A review of published findings. J Clin Oncol 2009; 27: 2339-2355.
8. Stevens MC, Mahler H, Parkes S. The health status of adult survivors of cancer in childhood. Eur J Cancer 1998; 34: 694-698.
9. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1582.
10. Johnson LA, Ross JA. Host factors and consequence of chemotherapy in pediatric cancer patients. Pediatr Blood Cancer 2008; 51: 320-326.
11. Hartford CM, Dolan ME. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 2007; 8: 1159-1168.
12. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1: 99-108.
13. Armenian SH, Bhatia S. Chronic health conditions in childhood cancer survivors: Is it all treatment-related-or do genetics play a role? J Gen Intern Med 2009; 24: S395-S400.
14. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: Role of Polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group. J Clin Oncol 2012; 30: 1415-1421.
15. Kadan-Lottick NS, Robison LL, Gurney JG, et al. Childhood cancer survivors' knowledge about their past diagnosis and treatment. Childhood cancer survivor study. JAMA 2002; 287: 1832-1839.
16. Hewitt M, Greenfield S, Stovall E. Cancer patient to cancer survivor: Lost in transition. Washington, DC: National Academies Press; 2006.
17. Hewitt MWS, Simone JV, editors. Childhood cancer survivorship: Improving care and quality of life. Washington, DC: National Academies Press; 2003.
18. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group. J Clin Oncol 30: 1663-1669.
19. Bhatia S, Sather HN, Heerema NA, et al. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 2002; 100: 1957-1964.
20. Koren G, Ferrazini G, Sulh H, et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 1990; 323: 17-21.
21. Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: A problem of non-compliance? BMJ 1993; 306: 1239-1240.
22. Lau RC, Matsui D, Greenberg M, et al. Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. Medical Pediatr Oncol 1998; 30: 85-90.
23. Yang Y, Thumula V, Pace PF, et al. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: A retrospective cohort study. Clin Ther 2009; 31: 2178-2188; discussion 2150-2171.
24. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol 2012; 30: 2094-2101.
25. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369: 2106-2120.
26. Henderson TO, Bhatia S, Pinto N, et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: A Children's Oncology Group study. J Clin Oncol 2011; 29: 76-82.
27. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: Rates, trends, and epidemiology. Curr Opin Oncol 2001; 13: 160-166.
28. Sands SA, Zhou T, O'Neil SH, et al. Long-term follow-up of children treated for high-grade gliomas: Children's oncology group L991 final study report. J Clin Oncol 2012; 30: 943-949.
29. Kadan-Lottick NS, Brouwers P, Breiger D, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009; 114: 1746-1752.
30. Kadan-Lottick NS, Brouwers P, Breiger D, et al. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2009; 27: 5986-5992.
31. Woods WG. Curing childhood acute myeloid leukemia (AML) at the half-way point: Promises to keep and miles to go before we sleep. Pediatr Blood Cancer 2006; 46: 565-569.
32. Haddy TB, Mosher RB, Reaman GH. Late effects in long-term survivors after treatment for childhood acute leukemia. Clin Pediatr 2009; 48: 601-608.
33. Schultz KA, Chen L, Chen Z, et al. Health and risk behaviors in survivors of childhood acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2010; 55: 157-164.
34. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27: 127-145.
35. Gurney JG, Tersak JM, Ness KK, et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 2007; 120: e1229-e1236.
36. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart (British Cardiac Society) 2008; 94: 525-533.
37. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: Implications for screening and prevention. Pediatr Blood Cancer 2005; 44: 600-606.
38. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H: Quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008; 112: 2789-2795.
39. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes-A report from the Children's Oncology Group. J Clin Oncol 2012; 30: 1415-1421.
40. Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012; 30: 1422-1428.
41. Wong FL, Bhatia S, Kurian S, et al. Efficacy and cost-effectiveness of the Children's Oncology Group (COG) Long-term Follow-up (LTFU) Guidelines in reducing risk of congestive heart failure (CHF) in childhood cancer survivors (CCS). Am Soc Clin Oncol 2012; Meeting: 2012 ASCO Annual Meeting Abstract No: 9505.
42. 2010. Richtlijn follow-up na kinderkanker meer dan 5 jaar na diagnose. SKION, Den Haag/Amsterdam. www.skion.nl. Dutch Childhood Oncology Group, accessed 2012.
43. 2004 2012. Long term follow up of survivors of childhood cancer: A national clinical guideline. www.sign.ac.uk. Scottish Intercollegiate Guidelines Network. 2012.
44. 2005. In Therapy based long term follow up practice statement wwwcclgorguk United Kingdom Children's Cancer Study Group Late Effects Group Accessed 2012.
45. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: The AGREE project. Qual Saf Health Care 2003; 12: 18-23.
46. Graham R, Mancher M, Miller Wolman D, et al. Clinical practice guidelines we can trust: Institute of medicine. Washington, DC: The National Academies Press; 2011.
47. Green DM, Kawashima T, Stovall M, et al. Fertility of female survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol 2009; 27: 2677-2685.
48. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010; 28: 4831-4841.
49. Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 2010; 28: 332-339.
50. Jahnukainen K, Ehmcke J, Hou M, et al. Testicular function and fertility preservation in male cancer patients. Best Pract Res Clin Endocrinol Metab 2011; 25: 287-302.
51. Bryant J, Picot J, Levitt G, et al. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: A systematic review. Health Technol Assess 2007; 11: iii, ix-x, 1-84.
52. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25: 493-500.
53. Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011; 47: 1373-1379.
54. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008; 121: e387-e396.
55. Steinberger J, Sinaiko AR, Kelly AS, et al. Cardiovascular risk and insulin resistance in childhood cancer survivors. J Pediatr 2011; 160: 494-499.